BTIG Research Cuts Liquidia (NASDAQ:LQDA) Price Target to $25.00

Liquidia (NASDAQ:LQDA) had its price target decreased by BTIG Research from $29.00 to $25.00 in a research report released on Monday morning, Benzinga reports. BTIG Research currently has a buy rating on the stock.

A number of other equities research analysts also recently commented on LQDA. Needham & Company LLC reiterated a buy rating and set a $25.00 price objective on shares of Liquidia in a research report on Monday. Oppenheimer began coverage on Liquidia in a report on Tuesday, June 25th. They set a market perform rating for the company. Raymond James raised Liquidia from an outperform rating to a strong-buy rating in a research note on Monday. Finally, HC Wainwright reiterated a buy rating and issued a $32.00 target price on shares of Liquidia in a report on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $23.14.

Liquidia Price Performance

NASDAQ LQDA opened at $9.98 on Monday. The company has a market capitalization of $762.61 million, a P/E ratio of -6.40 and a beta of 0.32. Liquidia has a 12 month low of $5.71 and a 12 month high of $16.99. The company’s 50 day simple moving average is $11.99 and its 200 day simple moving average is $13.27.

Insider Buying and Selling at Liquidia

In other news, CFO Michael Kaseta sold 3,906 shares of the stock in a transaction that occurred on Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the sale, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at $3,914,234.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Liquidia news, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $100,904.09. Following the transaction, the chief executive officer now directly owns 818,932 shares of the company’s stock, valued at approximately $10,261,217.96. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction dated Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the sale, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at $3,914,234.17. The disclosure for this sale can be found here. Insiders have sold a total of 21,437 shares of company stock valued at $268,549 in the last 90 days. 31.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Patient Square Capital LP bought a new stake in Liquidia in the first quarter worth $105,942,000. Farallon Capital Management LLC bought a new position in shares of Liquidia in the 1st quarter valued at approximately $30,311,000. Vestal Point Capital LP acquired a new stake in Liquidia in the 4th quarter worth approximately $12,331,000. Kynam Capital Management LP boosted its position in Liquidia by 34.9% during the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock worth $32,461,000 after purchasing an additional 698,324 shares during the period. Finally, Jump Financial LLC acquired a new position in Liquidia during the fourth quarter valued at approximately $1,933,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).